表紙
市場調查報告書
商品編碼
1089964

細胞解離市場規模,佔有率及趨勢分析:各產品,各組織,各類型,各終端用戶,各地區展望,競爭策略,至2030年的各市場區隔預測

Cell Dissociation Market Size, Share & Trends Analysis By Product, By Tissue, By Type, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 208 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球細胞解離的市場規模,預計今後以13.5%的年複合成長率擴大,至2030年達到8億8,148萬美元。細胞為基礎的研究變得繁盛,製藥公司和生物科技企業數量增加,成為市場擴大的要素。

本報告提供全球細胞解離市場相關調查,市場概要,以及各產品,各組織,各類型,各終端用戶,各地區的趨勢,及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長要素,阻礙因素,機會,課題的分析
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • COVID-19細胞解離市場的影響

第5章 市場變數及預測

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 熱圖分析

第6章 全球細胞解離市場,各產品,2019年∼2030年(100萬美元)

  • 酵素的解離生成物
    • 膠原酵素
    • DNase
    • 彈性蛋白酶
    • 玻糖醛酸酶
    • 木瓜蛋白酶
    • 胰蛋白酶
  • 酵素的解離生成物
  • 設備

第7章 全球細胞解離市場,各組織,2019年∼2030年(100萬美元)

  • 結締組織
  • 表皮組織
  • 其他(骨骼及肌肉組織)

第8章 全球細胞解離市場,各類型,2019年∼2030年(100萬美元)

  • 細胞的剝離
  • 組織的解離

第9章 全球細胞解離市場,各終端用戶,2019年∼2030年(100萬美元)

  • 製藥公司、生物科技企業
  • 學術研究機關
  • 其他

第10章 全球細胞解離市場,各地區,2019年∼2030年(100萬美元)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第11章 企業簡介

  • Abeomics
  • AcceGen
  • Alstem
  • Becton
  • Biological Industries
  • Capricorn Scientific
  • Central Drug House
  • Cytiva
  • Dickinson and Company
  • Gemini Bio
  • Genlantis
  • Innovative Cell Technologies
  • Miltenyi Biotec
  • Neuromics
  • PromoCell GmbH
  • Roche Diagnostics
  • STEMCELL Technologies
  • Thermo Fisher Scientific
  • VitaCyte
  • Worthington Biochemical Corporation
目錄
Product Code: BIOT2230

Global Cell Dissociation Market projected to be worth USD 881.48 million by 2030.

According to SPER Market Research, the Cell Dissociation Market estimated to reach USD 881.48 million by 2030 with a CAGR of 13.5%. Growing occurrence of cell-based research, the growing figure of pharmaceutical and biotechnology companies; these are the fuel to the expansion of the market.

Impact of COVID-19 on the Cell Dissociation Market

The outbreak of COVID-19 has a positive impact on the growth of the market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Product, By Tissue, By type, By End-User, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: Abeomics, AcceGen, Alstem, Becton, Biological Industries, Capricorn Scientific, Central Drug House, Cytiva, Dickinson and Company, Gemini Bio, Genlantis, Innovative Cell Technologies, Miltenyi Biotec, Neuromics, PromoCell GmbH, Roche Diagnostics, STEMCELL Technologies, Thermo Fisher Scientific, VitaCyte, Worthington Biochemical Corporation

Driver:

Increasing research & development activities in biopharmaceutical companies, encouraging funding scenario for cancer research, growing occurrence and incidence of chronic and infectious diseases, growing focus on personalized medicine, growing government funding for cell-based research; are the key drivers for the market expansion.

Restraint:

Costly cell-based researches, short of of infrastructure for cell-based research in emerging economies, can restraint the expansion of the market.

Opportunity:

Growth opportunities in emerging markets, development in stem cell research, appearance of advanced tissue dissociation enzyme products, recognition of enzyme-free dissociation products over enzymatic dissociation products.

Challenges:

Survival of small players and new entrants, ethical concerns regarding research in cell biology, are the challenges of the market.

Global Cell Dissociation Market, By Product:

Based on the Product, Global Cell Dissociation Market is segmented as; Enzymatic Dissociation Products (Collagenase, DNase, Elastase, Hyaluronidase, Papain, Trypsin), Enzymatic Dissociation Products, Instruments.

Global Cell Dissociation Market, By Tissue:

Based on the Tissue, Global Cell Dissociation Market is segmented as; Connective Tissues, Epithelial Tissues, Other type tissues (skeletal and muscles tissues).

Global Cell Dissociation Market, By Type:

Based on the Type, Global Cell Dissociation Market is segmented as; Cell detachment, Tissue dissociation.

Global Cell Dissociation Market, By End-User:

Based on the End-User, Global Cell Dissociation Market is segmented as; Pharmaceutical and Biotechnology companies, Research and Academics, other end users.

Global Cell Dissociation Market, By Region:

North America owns the biggest share of the market; this is due to the concentration of giant companies and growing research in Pharma and biopharma companies.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Cell Dissociation Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cell Dissociation Market, By Product, 2019-2030 (USD Million)

  • 6.1. Enzymatic Dissociation Products
    • 6.1.1. Collagenase
    • 6.1.2. DNase
    • 6.1.3. Elastase
    • 6.1.4. Hyaluronidase
    • 6.1.5. Papain
    • 6.1.6. Trypsin
  • 6.2. Enzymatic Dissociation Products
  • 6.3. Instruments

7. Global Cell Dissociation Market, By Tissue, 2019-2030 (USD Million)

  • 7.1. Connective Tissues
  • 7.2. Epithelial Tissues
  • 7.3. Other type tissues (skeletal and muscles tissues)

8. Global Cell Dissociation Market, By Type, 2019-2030 (USD Million)

  • 8.1. Cell detachment
  • 8.2. Tissue dissociation

9. Global Cell Dissociation Market, By End-User, 2019-2030 (USD Million)

  • 9.1. Pharmaceutical and Biotechnology companies
  • 9.2. Research and Academics
  • 9.3. other end users

10. Global Cell Dissociation Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. Abeomics
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. AcceGen
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Alstem
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Becton
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Biological Industries
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Capricorn Scientific
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Central Drug House
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cytiva
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Dickinson and Company

Company details

Financial outlook

Product summary

Recent developments

  • 11.10. Gemini Bio
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Genlantis
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. Innovative Cell Technologies
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Miltenyi Biotec
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Neuromics
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. PromoCell GmbH
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Roche Diagnostics
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. STEMCELL Technologies
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Thermo Fisher Scientific
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. VitaCyte
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Worthington Biochemical Corporation
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments

10. Global Cell Dissociation Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. Abeomics
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. AcceGen
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Alstem
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Becton
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Biological Industries
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Capricorn Scientific
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Central Drug House
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cytiva
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Dickinson and Company

Company details

Financial outlook

Product summary

Recent developments

  • 11.10. Gemini Bio
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Genlantis
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. Innovative Cell Technologies
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Miltenyi Biotec
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Neuromics
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. PromoCell GmbH
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Roche Diagnostics
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. STEMCELL Technologies
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Thermo Fisher Scientific
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. VitaCyte
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Worthington Biochemical Corporation
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments